C71T
CANCELLED SECTION 71
24/07/2026
Voltar para busca
Dado oficial do USPTO
EVOLYBRI
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
18/08/2026
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
25/06/2019
Data de registro
07/01/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/07/2026
Última transação
18/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
Basel, CH
Examinador
MAHMOUDI, MARIAM AZIZ
Unidade examinadora
M60
Localização atual
POST REGISTRATION
Titulares e representantes
Titulares
NOVARTIS AG
NOVARTIS AG
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma * excluding pharmaceutical preparations in the field of cardiovascularcardiacvascular and hematological diseases and disorders *
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
07/01/2025
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
07/01/2021
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
05/01/2021
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
28/04/2020
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
28/04/2020
PLGL
ASSIGNED TO PARALEGAL
23/04/2020
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
30/03/2020
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
27/03/2020
ES7R
TEAS SECTION 7 REQUEST RECEIVED
25/03/2020
GPNX
NOTIFICATION PROCESSED BY IB
20/03/2020
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
13/03/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
29/02/2020
FIMP
FINAL DISPOSITION PROCESSED
28/02/2020
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
06/02/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
07/01/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
22/10/2019
PUBO
PUBLISHED FOR OPPOSITION
22/10/2019
GPNX
NOTIFICATION PROCESSED BY IB
19/10/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/10/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/10/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/10/2019
ALIE
ASSIGNED TO LIE
18/09/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
16/09/2019
DOCK
ASSIGNED TO EXAMINER
13/09/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/09/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/09/2019
MAFR
APPLICATION FILING RECEIPT MAILED
03/09/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/08/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
20/08/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
15/08/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EVOLYBRI ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.